Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: In vitro and in vivo studies

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 1, 2013, Pages 63-71

  Sabzevari, Araz ^a,b   Adibkia, Khosro ^c   Hashemi, Hassan ^d,e   Hedayatfar, Alireza ^d   Mohsenzadeh, Navid ^d,e   Atyabi, Fatemeh ^a,b   Ghahremani, Mohammad Hossein ^b   Dinarvand, Rassoul ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d NOOR EYE HOSPITAL   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Laser flare meter; Nanoparticles; Nitric oxide; PLGA; Triamcinolone acetonide; Uveitis

Indexed keywords

FIBRIN; NANOPARTICLE; NITRIC OXIDE; POLYGLACTIN; PREDNISOLONE ACETATE; PROSTAGLANDIN E2; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; EMULSION; EXPERIMENTAL RABBIT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SLIT LAMP; UVEITIS; X RAY POWDER DIFFRACTION;

ANIMALS; AQUEOUS HUMOR; FEMALE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; RABBITS; RANDOM ALLOCATION; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; UVEITIS; X-RAY DIFFRACTION;

EID: 84876932998     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.12.010     Document Type: Article

References (53)

1. C.S. Foster, and A.T. Vitale Diagnosis and Treatment of Uveitis 2002 WB Saunders Co. Philadelphia
2. L. Lajavardi, S. Camelo, F. Agnely, W. Luo, B. Goldenberg, M.C. Naud, F. Behar-Cohen, and Y. de Kozak New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis J. Controlled Release 139 2009 22 30
3. F. Audren, A. Erginay, B. Haouchine, R. Benosman, J. Conrath, J.F. Bergmann, A. Gaudric, and P. Massin Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial Acta Ophthalmol. Scand. 84 2006 624 630
4. N. Benhamou, P. Massin, B. Haouchine, F. Audren, R. Tadayoni, and A. Gaudric Intravitreal triamcinolone for refractory pseudophakic macular edema Am. J. Ophthalmol. 135 2003 246 249
5. D.W. Parke Ii Intravitreal triamcinolone and endophthalmitis Am. J. Ophthalmol. 136 2003 918 919
6. Y.M. Kim, J.O. Lim, H.K. Kim, S.Y. Kim, and J.P. Shin A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide Eur. J. Pharm. Biopharm. 70 2008 179
7. C.N.J. McGhee, S. Dean, and H. Danesh-Meyer Locally administered ocular corticosteroids: benefits and risks Drug Saf. 25 2002 33 55
8. A. Zimmer, and J. Kreuter Microspheres and nanoparticles used in ocular delivery systems Adv. Drug Deliv. Rev. 16 1995 61 73
9. Y. Ali, and K. Lehmussaari Industrial perspective in ocular drug delivery Adv. Drug Deliv. Rev. 58 2006 1258 1268
10. D.T.H. Tan, S.P. Chee, L. Lim, and A.S.M. Lim Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation Ophthalmology 106 1999 223 231
11. C. Gómez-Gaete, N. Tsapis, L. Silva, C. Bourgaux, M. Besnard, A. Bochot, and E. Fattal Supramolecular organization and release properties of phospholipid-hyaluronan microparticles encapsulating dexamethasone Eur. J. Pharm. Biopharm. 70 2008 116 126
12. K.M. Sampat, and S.J. Garg Complications of intravitreal injections Curr. Opin. Optholmol. 21 2010 178
13. M. Colthurst, R. Williams, P. Hiscott, and I. Grierson Biomaterials used in the posterior segment of the eye Biomaterials 21 2000 649 665
14. M. Mosharraf, and C. Nyström The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs Int. J. Pharm. 122 1995 35 47
15. S. Tamilvanan, and S. Benita The potential of lipid emulsion for ocular delivery of lipophilic drugs Eur. J. Pharm. Biopharm. 58 2004 357 368
16. R. Pignatello, C. Bucolo, P. Ferrara, A. Maltese, A. Puleo, and G. Puglisi Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen Eur. J. Pharm. Sci. 16 2002 53 61
17. H.S.M. Ali, P. York, A. Ali, and N. Blagden Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling J. Controlled Release 149 2011 175 181
18. M. Kassem, A. Abdel Rahman, M. Ghorab, M. Ahmed, and R. Khalil Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs Int. J. Pharm. 340 2007 126 133
19. P. Calvo, A. Sánchez, J. Martínez, M.I. López, M. Calonge, J.C. Pastor, and M.J. Alonso Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A Pharm. Res. 13 1996 311 315
20. C. Losa, P. Calvo, E. Castro, J. VILA-JATO, and M. Alonso Improvement of ocular penetration of amikacin sulphate by association to poly (butylcyanoacrylate) nanoparticles J. Pharm. Pharmacol. 43 1991 548 552
21. C. Losa, L. Marchal-Heussler, F. Orallo, J.L.V. Jato, and M.J. Alonso Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol Pharm. Res. 10 1993 80 87
22. M.G. Qaddoumi, H. Ueda, J. Yang, J. Davda, V. Labhasetwar, and V.H.L. Lee The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers Pharm. Res. 21 2004 641 648
23. A.K. Zimmer, P. Maincent, P. Thouvenot, and J. Kreuter Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles Int. J. Pharm. 110 1994 211 222
24. F. Esmaeili, M.H. Ghahremani, B. Esmaeili, M.R. Khoshayand, F. Atyabi, and R. Dinarvand PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution Int. J. Pharm. 349 2008 249 255
25. R. Dinarvand, N. Sepehri, S. Manoochehri, H. Rouhani, and F. Atyabi Poly lactide-co-glycolide nanoparticles for controlled delivery of anticancer agents Int. J. Nanomed. 6 2011 877
26. K. Tahara, Y. Miyazaki, Y. Kawashima, J. Kreuter, and H. Yamamoto Brain targeting with surface-modified poly (d,l-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration Eur. J. Pharm. Biopharm. 77 2011 84 88
27. Y. Javadzadeh, F. Ahadi, S. Davaran, G. Mohammadi, A. Sabzevari, and K. Adibkia Preparation and physicochemical characterization of naproxen-PLGA nanoparticles Colloids Surf., B: Biointerf. 81 2010 498 502
28. J. Rosenbaum, H. McDevitt, R. Guss, and P. Egbert Endotoxin-induced uveitis in rats as a model for human disease Nature 1980 611 613
29. J.T. Rosenbaum, and W. Raymond Monocyte chemotactic activity induced by intravitreal endotoxin Invest. Ophthalmol. Visual Sci. 26 1985 1267 1273
30. J. Bellot, M. Palmero, C. Garcia-Cabanes, R. Espi, C. Hariton, and A. Orst Additive effect of nitric oxide and prostaglandin-E 2 synthesis inhibitors in endotoxin-induced uveitis in the rabbit Inflamm. Res. 45 1996 203 208
31. K. Adibkia, M.R.S. Shadbad, A. Nokhodchi, A. Javadzedeh, M. Barzegar-Jalali, J. Barar, G. Mohammadi, and Y. Omidi Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis J. Drug Target. 15 2007 407 416
32. K. Ohgami, I. Ilieva, K. Shiratori, Y. Koyama, X.H. Jin, K. Yoshida, S. Kase, N. Kitaichi, Y. Suzuki, and T. Tanaka Anti-inflammatory effects of aronia extract on rat endotoxin-induced uveitis Invest. Ophthalmol. Visual Sci. 46 2005 275 281
33. M. Sawa Clinical application of laser flare-cell meter Jpn. J. Ophthalmol. 34 1990 346
34. J.G. Ladas, N.C. Wheeler, P.J. Morhun, S.O. Rimmer, and G.N. Holland Laser flare-cell photometry: methodology and clinical applications Surv. Ophthalmol. 50 2005 27 47
35. 2-adrenergic agonists on lipopolysaccharide-induced aqueous flare elevation in pigmented rabbits Jpn. J. Ophthalmol. 45 2001 221 226
36. C. Gómez-Gaete, N. Tsapis, M. Besnard, A. Bochot, and E. Fattal Encapsulation of dexamethasone into biodegradable polymeric nanoparticles Int. J. Pharm. 331 2007 153 159
37. S. Simovic, and C.A. Prestidge Nanoparticle layers controlling drug release from emulsions Eur. J. Pharm. Biopharm. 67 2007 39 47
38. M.B. Sewer, T.B. Barclay, and E.T. Morgan Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene Mol. Pharmacol. 54 1998 273 279
39. F. Esmaeili, F. Atyabi, and R. Dinarvand Preparation of PLGA nanoparticles using TPGS in the spontaneous emulsification solvent diffusion method J. Exp. Nanosci. 2 2007 183 192
40. A. Layre, P. Couvreur, H. Chacun, J. Richard, C. Passirani, D. Requier, J. Benoit, and R. Gref Novel composite core-shell nanoparticles as busulfan carriers J. Controlled Release 111 2006 271 280
41. A.M. Layre, R. Gref, J. Richard, D. Requier, H. Chacun, M. Appel, A.J. Domb, and P. Couvreur Nanoencapsulation of a crystalline drug Int. J. Pharm. 298 2005 323 327
42. S. Verma, R. Gokhale, and D.J. Burgess A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions Int. J. Pharm. 380 2009 216 222
43. C. Patronidou, P. Karakosta, K. Kotti, O. Kammona, V. Karageorgiou, and C. Kiparissides PLGA nanocarriers for systemic and lymphatic oral delivery of proteins and peptides J. Controlled Release 132 2008 e5 e6
44. A. Budhian, S.J. Siegel, and K.I. Winey Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content Int. J. Pharm. 336 2007 367 375
45. S. Douglas, S. Davis, and L. Illum Nanoparticles in drug delivery Crit. Rev. Ther. Drug Carrier Syst. 3 1987 233
46. L.N. Fleisher, J.B. Ferrell, and M.C. McGahan Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin Inflammation 14 1990 325 335
47. R.B. Nussenblatt, D. Calogero, S.Y. Buchen, H.A. Leder, M. Goodkin, and M.B. Eydelman Rabbit intraocular reactivity to endotoxin measured by slit-lamp biomicroscopy and laser flare photometry Ophthalmology 119 2012 e19 e23
48. K. Baba, Y. Tanaka, A. Kubota, H. Kasai, S. Yokokura, H. Nakanishi, and K. Nishida A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolysable dye J. Controlled Release 153 2011 278 287
49. L. Marchal-Heussler, H. Fessi, J.P. Devissaguet, M. Hoffman, and P. Maincent Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: polyisobutylcyanoacrylate, polylactic-co-glycolic acid, poly-epsilon-caprolacton J. Drug Deliv. Sci. Technol. 2 1992 98 104
50. T. Oshika, M. Araie, and K. Masuda Diurnal variation of aqueous flare in normal human eyes measured with laser flare-cell meter Jpn. J. Ophthalmol. 32 1988 143
51. K. Kamata, M. Inazu, H. Takeda, H. Goto, T. Matsumiya, and M. Usui Effect of a selective inducible nitric oxide synthase inhibitor on intraocular nitric oxide production in endotoxin-induced uveitis rabbits: in vivo intraocular microdialysis study Pharmacol. Res. 47 2003 485 491
52. X.H. Jin, K. Ohgami, K. Shiratori, Y. Suzuki, T. Hirano, Y. Koyama, K. Yoshida, I. Ilieva, K. Iseki, and S. Ohno Inhibitory effects of lutein on endotoxin-induced uveitis in Lewis rats Invest. Ophthalmol. Visual Sci. 47 2006 2562 2568
53. Y. Yomura, Y. Shoji, D. Asai, E. Murakami, S. Ueno, and H. Nakashima Direct, real-time, simultaneous monitoring of intravitreal nitric oxide and oxygen in endotoxin-induced uveitis in rabbits Life Sci. 80 2007 1449 1457